country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-183302

Copy Link Print Information

Anticancer agent 317

Anticancer agent 317, a Chidamide (HY-109015) derivative, is an apoptosis inducer. Anticancer agent 317 inhibits colony formation, migration, adhesion, invasion, tumor growth, and angiogenesis. Anticancer agent 317 can be used for the research of breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3117779-13-9
Formel: C₄₇H₄₇ClFN₉O₃S
Molecular Weight:872.45

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Anticancer agent 317 Chemical Structure

CAS. Nr.: 3117779-13-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Anticancer agent 317 (Compound 6e) potently and selectively inhibits proliferation of MDA-MB-231 breast cancer cells with an IC₅₀ of 0.10 μM^[1].
Anticancer agent 317 (0.025-0.1 μM; 24 h) dose-dependently inhibits long-term colony formation of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.025 μM^[1].
Anticancer agent 317 (0.025-0.1 μM; 48 h) dose-dependently induces apoptosis in MDA-MB-231 breast cancer cells, with the highest level of apoptosis observed at 0.1 μM^[1].
Anticancer agent 317 (0.01-0.04 μM; 24 h) dose-dependently inhibits adhesion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM^[1].
Anticancer agent 317 (0.01-0.04 μM; 24-48 h) dose-dependently inhibits invasion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM^[1].
Anticancer agent 317 (0.025-0.1 μM) dose-dependently inhibits angiogenesis and tumor growth in a chicken embryo CAM model of breast cancer, with the 0.1 μM dose reducing tumor weight to 8.33 mg and angiogenesis to 51.79% of control levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MDA-MB-231
Concentration:

0.025 μM; 0.05 μM; 0.1 μM
Incubation Time:

24 h
Result:

Dose-dependently reduced colony-forming ability of MDA-MB-231 cells, with colony formation rates of 66.17% at 0.025 μM, 50.00% at 0.05 μM, and 33.46% at 0.1 μM.
Showed stronger inhibitory activity than chidamide (86.07% colony formation rate) at 0.1 μM.

Apoptosis Analysis^[1]

Cell Line:

MDA-MB-231
Concentration:

0.025 μM; 0.05 μM; 0.1 μM
Incubation Time:

48 h
Result:

Dose-dependently increased the proportion of Annexin V-positive apoptotic cells.
Markedly elevated the proportion of apoptotic cells (Annexin V-positive, PI-positive/negative) compared to untreated control at 0.1 μM, with 21.16% of cells in the early apoptotic quadrant and 29.33% in the late apoptotic quadrant.

Cell Migration Assay ^[1]

Cell Line:

MDA-MB-231
Concentration:

0.01 μM; 0.02 μM; 0.04 μM
Incubation Time:

24 h; 48 h
Result:

Inhibited migration capacity at both 24 h and 48 h.
Reduced migration rates to 66.65% at 0.01 μM, 50.42% at 0.02 μM, and 30.99% at 0.04 μM after 48 h.
Showed stronger inhibitory activity than chidamide (51.69% migration rate at 48 h) at 0.04 μM.

Related Protocols :

Chemical Information

CAS. Nr. 3117779-13-9
Molecular Weight 872.45
Formel C₄₇H₄₇ClFN₉O₃S
SMILES

CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(NCCCCCCNC5=CC(F)=CC=C5NC(C6=CC=C(C=C6)CNC(/C=C/C7=CC=CN=C7)=O)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Zhou Y, et al. Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. Bioorg Med Chem Lett. 2026;137:130652. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen